Sumit Gaur

Dr. Sumit Gaur

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012
Verified
Open access
SGSumit Gaur
Sumit Gaur
ATAlireza Torabi
Alireza Torabi
TOThomas J O’Neill
Thomas J O’Neill
This report describes a patient with metastatic epithelioid hemangioendothelioma treated with bevacizumab and nanoparticle albumin-bound paclitaxel. The treatment was well tolerated and led to the stabilization of an aggressive variant of the disease. This case report is the first one that describes the activity of the combination of chemotherapy and bevacizumab in epithelioid hemangioendothelioma. Literature describing the activity of bevacizumab and other agents (thalidomide, lenalidomide, and interferon) believed to possess anti-angiogenic activities is also reviewed.

3 January 2013 in Lymphoma
Verified
Journal Article
Open access
PDF file
SGSumit Gaur
Sumit Gaur
OPOsvaldo Padilla
Osvaldo Padilla
ZNZeina Nahleh
Zeina Nahleh
Cluster designation (CD) 20 antigen is expressed on most B-cell lymphomas and serves as a therapeutic target for rituximab. A small minority of aggressive B-cell lymphomas, predominantly plasmablastic variants, do not express CD 20. We systematically reviewed all cases of aggressive B-cell lymphomas diagnosed at our institution over a period of 13 years. Of the 232 cases, 7 did not express CD 20. Five of these were plasmablastic lymphomas while two were unclassifiable B-cell lymphomas. While most of the plasmablastic lymphomas responded to chemotherapy, patients with unclassifiable lymphomas were primarily refractory or relapsed soon after chemotherapy.


28 May 2013 in Breast Disease
Verified
Journal Article
Closed access
PDF file
SGSumit Gaur
Sumit Gaur
AAAnoop P. Ayyappan
Anoop P. Ayyappan
ZNZeina Nahleh
Zeina Nahleh
Metastases to the breast from non-mammary sites are rare and pose a diagnostic and therapeutic challenge. They can be mistaken for primary breast malignancy, which is much more common. In this case report we describe the clinical, radiological and pa

13 September 2019 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
OUOnyedika Umeanaeto
Onyedika Umeanaeto
JGJoseph Gamboa
Joseph Gamboa
JDJesus Diaz
Jesus Diaz
MHM. Nawar Hakim
M. Nawar Hakim
JCJavier Corral
Javier Corral
SGSumit Gaur
Sumit Gaur
Incorporating bortezomib and/or lenalidomide in the management of plasmablastic lymphoma is an attractive option due to the reported high response rates. However, concerns about overlapping toxicities can deter clinicians from incorporating these novel agents into chemotherapy. In this case report we describe a patient with plasmablastic lymphoma, who received both lenalidomide and bortezomib as part of upfront treatment for a high-risk plasmablastic lymphoma. After completing intensive chemotherapy, the patient was transitioned to a regimen of daily lenalidomide and biweekly bortezomib to decrease the chance of relapse. This maintenance phase was given for 6 months and was well tolerated. Despite having multiple adverse risk factors, the patient remains in remission, 18 months following diagnosis.

28 February 2013 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
SSSrikanth Seethala
Srikanth Seethala
SGSumit Gaur
Sumit Gaur
EEElizabeth Enderton
Elizabeth Enderton
JCJavier Corral
Javier Corral
A 36-year-old female started having postpartum vaginal bleeding after normal vaginal delivery. She underwent hysterectomy for persistent bleeding and was referred to our institution. An elevation of PTT and normal PT made us suspect postpartum acquired hemophilia (PAH), and it was confirmed by low factor VIII activity levels and an elevated factor VIII inhibitor. Hemostasis was achieved with recombinant factor VII concentrates and desmopressin, and factor eradication was achieved with cytoxan, methylprednisolone, and plasmapheresis.